Difference between revisions of "Profiles"

From QIBA Wiki
Jump to navigation Jump to search
m
 
(82 intermediate revisions by 3 users not shown)
Line 4: Line 4:
 
Profiles '''[[How to use QIBA Profiles|may be of use]]''' at any Stage.
 
Profiles '''[[How to use QIBA Profiles|may be of use]]''' at any Stage.
  
−
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles===
+
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles===
  
−
*[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf | MR Elastography of the Liver 2022-02-14]]
+
*[[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf|CT Atherosclerosis Biomarkers, Clinically Feasible Profile. March 28, 2023. doi:10.1148/QIBA/20230328]]
  
−
* [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean-3.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]]
+
*[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2023.12.19.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening, Clinically Feasible Profile. December 19, 2023. doi:10.1148/QIBA/20231219]]
  
−
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_TechConfirmed-20180622a.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22]]
+
*[[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease, Clinically Feasible Streamlined Profile including Conformance Checklists. July 21, 2022. doi:10.1148/QIBA/20220721]]
−
:* Conformance Checklists (refer to Appendix C in the Profile document - pg 42)
 
−
:* Assessment Procedures (refer to Section 4 in the Profile document - pg 30)
 
  
−
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
+
*[[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC), Clinically Feasible Profile. December 15, 2022. doi:10.1148/QIBA/20221215]]
−
:* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]
 
  
−
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
+
*[[Media:MRE-QIBAProfile-2023-11-07-CLINICALLY-FEASIBLE-maintenance.pdf|MR Elastography of the Liver, Clinically Feasible Profile: ''Maintenance draft''. November 7, 2023. doi:10.1148/QIBA/20231107]]
 +
**[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf|MR Elastography of the Liver, Clinically Feasible Profile. February 2, 2022.]]
  
−
*[[Media:QIBA_CTA_Profile_as_of_2020-Mar-10.pdf| CTA Atherosclerosis 2020-03-10]]
+
*[[Media:Supplement QIBA AmyloidPET 3Jun2022 TechnicallyConfirmed.pdf|PET Amyloid, Clinically Feasible Profile. June 3, 2022. doi:10.1148/QIBA/20220603]]
−
:*[[Media:QIBA_CTA_Field Test Checklist.xlsx| CTA Atherosclerosis Checklist 2020-05-28]]
 
  
−
*[[Media:QIBA_CT_Lung_Density_Profile_090420-clean.pdf | CT Lung Density Profile_09.04.2020, clean version]] (Contains Conformance Checklist, Appendix B) 2020-10-23
+
*[[Media:QIBA FDG-PET Profile v114.pdf|PET/CT FDG SUV for Response to Cancer Therapy, v1.14, Clinically Feasible Profile containing updated checklist. June 15, 2023. doi:10.1148/QIBA/20230816]]
−
:*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Appendix E:CT Lung Density Protocols 2019-06-26]]  
+
*[[Media:QIBA FDG-PET Profile v113.pdf|PET/CT FDG SUV for Response to Cancer Therapy, v1.13, Clinically Feasible Profile. November 18, 2016.]]
 +
::*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0. December, 2014.]]
  
−
*[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification v1.0 2012-08-08]]
+
*[[Media:QIBA US SWS Profile 01.15.2024-clean version.pdf| US Shear Wave Speed for Liver Fibrosis, Clinically Feasible Profile. January 15, 2024. doi:10.1148/QIBA/20240115]]
 +
::*[[Media:SWS Checklists-Appendix E-12.28.2023.xlsx|Checklists - US SWS Appendix E. December 28, 2023]]
 +
::*[[Media:SWS Checklists-Appendix E-01.26.2023.xlsx|US SWS Checklist for Clinically Feasible Site Assessment. January 26, 2023]]
  
−
*[[Media:QIBA_DWIProfile_Consensus_Dec2019_Final.pdf| MR Diffusion-Weighted Imaging (DWI) 2019-12-20]]
+
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
  
−
*[[Media:QIBA_DSC-MRI_Stage2-Consensus_Profile.pdf| MR Dynamic Contrast Susceptibility (DSC) 2020-10-22]]
+
*[[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density 2020-09-04]] (Contains Conformance Checklists, Appendix B) 2020-10-23
 +
::*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Protocols - Appendix E:CT Lung Density 2019-06-26]]
  
−
*[[Media:MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf | MR Elastography of the Liver 2018-05-02]]  
+
*[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification (V.1) 2012-08-08]]
  
−
*[[Media:QIBA_Profile_MSK-Cartilage-Stage2_Profile.pdf| MR MSK cartilage for joint disease 2021-09-25]]
+
*[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility 2020-10-22]]
  
−
*[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | PET F-18 for Amyloid 2018-06-20]]  
+
*[[Media:QIBA Profile MSK-Cartilage-Stage2 Profile.pdf| MR MSK Cartilage for Joint Disease 2021-09-25]]
  
−
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Ioflupane for Neurodegenerative Disease v1.1, 2017-06-26]]
+
*[[Media:001.QIBA SPECT Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf| SPECT Ioflupane for Neurodegenerative Disease 2017-06-26]]
−
 
 
−
*[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf | SPECT Ioflupane for Neurodegenerative Disease v2.0, 2019-10-15]]
 
−
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
 
−
 
 
−
*[[Media:QIBA_SPECT_99mTC_Profile_10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]
 
−
 
 
−
*[[Media:QIBA_US_SWS_Profile_04.25.2022-clean version.pdf|US Shear Wave Speed for Liver Fibrosis-2022-04-25]] (clean version - Consensus vote)
 
−
:*[[Media:SWS Checklists-Appendix E-04.25.2022.xlsx|Appendix E: SWS Checklists]] (updated April 25, 2022)
 
  
 +
*[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane for Neurodegenerative Disease 2019-10-15]]
 +
::*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklists - SPECT Ioflupane]]
  
 +
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]
  
 +
*[[Media:QIBA US VBF Profile 01.05.2024-Consensus.pdf| US Volume Blood Flow Profile, Consensus version 2024-01-05]]
  
 +
*[[Media:QIBA PDFF Profile Stage2 FINAL.pdf|MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]]
  
 +
*[[Media:QIBA DCE-Profile - v2.0 - Consensus Document.pdf|MR DCE-MRI Quantification (DCEMRI-Q) (V.2) 2023-12-06]]
  
 
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
 
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
 +
*[[Media:QIBA fMRI Profile 1 PC-rev1.pdf|fMRI for Sensorimotor Mapping 2017-06-19]] (comments '''closed''' on December 31, 2017)
  
−
'''Please submit comments using the '''[https://forms.gle/bPzUAuLKJnHYGbVS7 '''online form''']'''
 
−
 
−
*[[Media:QIBA_DCE-MRI_Profile-Stage_1-Public_Comment.pdf|MR DCE-MRI Quantification (DCEMRI-Q) 2020-10-12]] ('''closed''' on March 10, 2021)
 
−
 
−
*[[Media:QIBA_Profile_MSK-Cartilage-Stage1_Profile.pdf|MR MSK cartilage for joint disease 2020-05-18]] ('''closed''' on October 29, 2020)
 
−
 
−
*[[Media:QIBA_US_SWS_Profile_10.21.19.pdf|US Shear Wave Speed for Liver Fibrosis 2019-10-21]] ('''closed''' on December 18, 2019)
 
−
 
−
:*[[Media:SWS Checklists-Appendix E.xlsx|Appendix E: SWS Checklists, 2019-10-21]] ('''closed''' on December 18, 2019)
 
  
−
*[[Media:QIBA_fMRI_Profile_1_PC-rev1.pdf| fMRI for Sensorimotor Mapping 2017-06-19]] ('''closed''' on December 31, 2017)
+
'''[[Comment Resolutions]]''' <font color="black">are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.
  
 +
'''Tools to aid Biomarker Committees in collating these comments:'''
 +
* {Public Comment Resolution} - '''Editor''' collates all comments into a '''resolution spreadsheet''' (see '''[https://docs.google.com/spreadsheets/d/1o3_ssHHIABGKNesUJ_-jL5RYqSx9Eq4o6C2dlIsHQo4/edit?usp=sharing Google Sheet template)]'''
 +
* {Site responses for Stage 3} - '''Field Test Leader''' collates all Feedback comments into a '''[https://docs.google.com/spreadsheets/d/1JW-_iJ7vTJvCf1-y4wsxZ_coO8Po2zWqMNDNrBVyUXM/edit?usp=sharing Feedback Resolution spreadsheet]''' 
 +
'''
  
−
'''[[Comment Resolutions]]''' <font color=black>are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.<font>
 
  
 +
'''[[Media:QIBA Profiles and Clinical Applications-v01Nov2023-2.xlsx|QIBA Profiles and Clinical Applications]]'''
  
 +
 
====Format for Citing Profiles====
 
====Format for Citing Profiles====
 
Cite QIBA Profile documents as:
 
Cite QIBA Profile documents as:
  
−
: ''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Version. Profile Stage''. ''Date''. Available from: ''URL''
+
:''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Profile Stage''. ''Date''. Available from: ''URL''
  
 
Example:
 
Example:
  
−
: QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
+
:QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
  
  

Latest revision as of 19:24, 18 April 2024

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Clinically Feasible (formerly Technically Confirmed) Profiles

Stage 2: Consensus Profiles

Stage 1: Public Comment Profiles


Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.

Tools to aid Biomarker Committees in collating these comments:


QIBA Profiles and Clinical Applications


Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Profile Stage. Date. Available from: URL

Example:

QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles


Statements of Endorsement


See Also
Retrieved from "https://qibawiki.rsna.org/index.php?title=Profiles&oldid=19672"